<DOC>
	<DOCNO>NCT00004294</DOCNO>
	<brief_summary>OBJECTIVES : I . Transfer human glucocerebrosidase ( GC ) gene peripheral blood stem cell ( PBSC ) obtain patient type I Gaucher disease use retroviral vector . II . Transplant autologous transduce PBSC patient . III . Measure carriage expression transfer gene duration peripheral blood leukocyte . IV . Assess clinical effect transplant genetically correct PBSC .</brief_summary>
	<brief_title>Phase I Study Retrovirally Mediated Transfer Human Glucocerebrosidase Gene Into Peripheral Blood Stem Cells Autologous Transplantation Patients With Type I Gaucher Disease</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients undergo autologous transplantation use peripheral blood stem cell ( PBSC ) stimulate filgrastim ( G-CSF ) transduce retroviral vector contain human glucocerebrosidase gene ( R-GC ) . Patients may receive 4 transplant deficient glucocerebrosidase level find peripheral leukocyte 1 month follow transplantation . The G-CSF-stimulated PBSC enrich CD34-positive stem cell transduce R-GC vector . Stem cell normal gene activity select transplantation . Patients follow every month 6 month , every 6 month 18 month , annually thereafter .</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Enzyme proven type I Gaucher disease Glucocerebrosidase ( GC ) activity le 30 % normal GC mutation identify Significant sign symptom disease prior therapy initiation At least 1 follow 12 month therapy : Liver least 2 time normal size Spleen least 5 time normal size Platelet count great 150,000/mm3 Clinical bone disease pain , fracture , infarction Multiple sit marrow involvement Angiotensinconverting enzyme least 1.5 time normal No GC antibody At least 3 follow response therapy : Hemoglobin increase 2 g/dL Platelet count increase 50 % Spleen liver size decrease least 25 % Improvement MRI xray bone Nontartrate inhibitable acid phosphatase decrease 50 % Angiotensinconverting enzyme decrease 50 % OR Previously untreated immediate enzyme therapy would life save Meets least 2 follow criterion : Spleen least 5 time normal size liver least 2 time normal size physical exam MRI Hemoglobin le 11 g/dL Platelet count le 90,000/mm3 Disabling bone pain degenerative change xray Multiple sit bone marrow infiltration evidence bony change Pulmonary compromise club PaO2 le 70 mm Hg Biopsy proven cirrhosis elevate hepatic parenchymal enzyme Bleeding esophageal varix Prior/Concurrent Therapy At least 3 month since prior investigational therapy Concurrent enzyme replacement therapy may taper study Patient Characteristics HIV negative No malignant disease No known sensitivity egg murine product Not pregnant nursing Fertile patient must use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>Gaucher 's disease</keyword>
	<keyword>inborn error metabolism</keyword>
	<keyword>rare disease</keyword>
	<keyword>sphingolipidoses</keyword>
</DOC>